Fig. 3From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world studyKaplan–Meier analyses of time-to-progression according to A α-fetoprotein levels, B tumor size, C regorafenib dose, and D best responseBack to article page